1. Home
  2. Analysis

Death and drugs of ingredients of ocrelizumab (a real world drug study)


Summary:

Death is found among people who take drugs with ingredients of ocrelizumab, especially for people who are female, 60+ old , have been taking the drugs for < 1 month. This phase IV clinical study is created by eHealthMe based on reports of 65,780 people who have side effects when taking drugs with ingredients of ocrelizumab from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Ocrevus.

On Jun, 04, 2026

65,780 people reported to have side effects when taking drugs with ingredients of ocrelizumab.
Among them, 465 people (0.71%) died.

Number of reports submitted per year:

Could drugs with ingredients of ocrelizumab cause Death?

Time on drugs with ingredients of ocrelizumab when people died *:

  • < 1 month: 26.09 %
  • 1 - 6 months: 5.43 %
  • 6 - 12 months: 13.04 %
  • 1 - 2 years: 26.09 %
  • 2 - 5 years: 25.0 %
  • 5 - 10 years: 4.35 %
  • 10+ years: 0.0 %

Gender of people who died when taking drugs with ingredients of ocrelizumab *:

  • female: 60.18 %
  • male: 39.82 %

Age of people who died when taking drugs with ingredients of ocrelizumab *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 1.1 %
  • 30-39: 7.33 %
  • 40-49: 16.85 %
  • 50-59: 25.27 %
  • 60+: 49.45 %

Conditions people have *:

You may use this to check any potential undetected conditions.

Click here to view

Other drugs people take *:

You may use this to check any potential interacting drugs.

Click here to view

Other side effects people have when they died *:

Click here to view

* Approximation only. Some reports may have incomplete information.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Drugs with ingredients of ocrelizumab, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on ocrelizumab. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.